Core Viewpoint - Bio-Path (BPTH) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive shift in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of changing earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance Indicators - Bio-Path is projected to report earnings of -$3.17 per share for the fiscal year ending December 2024, reflecting a year-over-year change of 90.6% [7]. - Over the past three months, the Zacks Consensus Estimate for Bio-Path has increased by 48.9%, indicating a positive trend in earnings outlook [7]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [6]. - The upgrade to Zacks Rank 2 places Bio-Path in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

A downtrend has been apparent in Bio-Path (BPTH) lately. While the stock has lost 8.2% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the stoc ...

Financial Data and Key Metrics Changes - The company reported a net loss of $2.1 million, or $0.70 per share, for Q3 2024, compared to a net loss of $3.2 million, or $6.36 per share, for Q3 2023, indicating an improvement in financial performance [18] - Research and development expenses decreased to $1.3 million in Q3 2024 from $2.3 million in Q3 2023, primarily due to reduced manufacturing expenses and clinical trial costs [19] - General and administrative expenses increased to $1.3 million in Q3 2024 from $1.0 million in Q3 2023, mainly due to higher legal fees and salaries [20] - Cash reserves as of September 30, 2024, were $0.6 million, down from $1.1 million as of December 31, 2023 [20] - Net cash used in operating activities for the nine months ended September 30, 2024, was $7.7 million, compared to $9.7 million for the same period in 2023 [21] Business Line Data and Key Metrics Changes - The company is advancing its clinical development program for BP1001-A, targeting obesity and related metabolic diseases, marking a significant expansion of its DNAbilize platform beyond oncology [6][7] - Progress continues in the Phase 1/1b clinical trial of BP1001-A in patients with solid tumors, with a focus on safety evaluations [9] - The amended Stage 2 of the Phase 2 trial for prexigebersen in AML is ongoing, with a focus on achieving complete remission in patients [10] - The Phase 1/1b trial of BP1002 in refractory relapse AML patients is progressing, with initial dosing cohorts showing no dose-limiting toxicity [14] Market Data and Key Metrics Changes - The company is expanding its therapeutic focus to include obesity and metabolic diseases, which may open new market opportunities beyond its traditional oncology focus [6][8] - The ongoing trials for BP1001-A and BP1002 are being conducted at leading cancer centers, indicating a strong market presence and collaboration [9][14] Company Strategy and Development Direction - The company aims to deliver a new era of DNA-powered medicine, with a focus on expanding its DNAbilize platform into non-cancer applications [6] - There is a strategic emphasis on addressing unmet medical needs in both oncology and metabolic disease markets, which may enhance the company's growth potential [22] Management's Comments on Operating Environment and Future Outlook - Management expressed pride in the progress made and highlighted the potential of the DNAbilize platform to provide new treatment options for patients [6][22] - The company anticipates a strong finish to the year, driven by advancements across its pipeline and the introduction of new medicines [22] Other Important Information - The company has identified a method for oligo detection in trace quantities in plasma, which is expected to facilitate the submission of an investigational new drug application to the FDA for BP1003 [17] Q&A Session Summary - The Q&A session was brief, and no specific questions or answers were documented in the provided content [23]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Delaware 001-36333 87-0652870 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share BPTH The Nasdaq Capital Market FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 15, ...

Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2024 and provided an update on recent corporate developments. “The third quart ...

Table of Contents Delaware 87-0652870 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __ ...

HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 15, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024 and to provide a business overview. To access the live conference call, ...

. Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24 September 04, 2024 5:48 PM EDT | Source: Reportable, Inc. Dallas, Texas--(Newsfile Corp. - September 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q2 2024. To view the full announcement, including downloadable images, bios, and more, click here. Click image above to view full announcement. About Stonegate Stonegate Capital Partne ...

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q2 2024 Earnings Conference Call August 15, 2024 8:30 AM ET Company Participants Will O'Connor - IR, Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP of Finance, Accounting and Administration Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Second Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. [Operator Instructions] At this time, I'd like to turn the floor over to Will ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Delaware 001-36333 87-0652870 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share BPTH The Nasdaq Capital Market FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 15, 2 ...